BANGERLABS
Fulfilled in the USA Batch Produced & Tested Fast & Discreet Shipping ≥99% Purity Guaranteed COA Every Batch Independently Tested 24/7 Support Fulfilled in the USA Batch Produced & Tested Fast & Discreet Shipping ≥99% Purity Guaranteed COA Every Batch Independently Tested 24/7 Support
Banger.
Login / Register

CJC-1295 with DAC: Research Overview — Mechanism, Research Areas & References

By the Banger Labs Research Team · Updated June 2026

CJC-1295 with DAC research peptide

Short answer: CJC-1295 with DAC is a synthetic GHRH (GRF 1-29) analog engineered with a Drug Affinity Complex that covalently binds serum albumin to extend its circulating half-life in research settings. It is supplied strictly for laboratory and research use only; this overview makes no medical, therapeutic, efficacy, dosage, or human-use claims, and the compound is not an FDA-approved drug.

What is CJC-1295 with DAC?

CJC-1295 with DAC (also referred to in the literature as DAC:GRF) is a synthetic analog of the first 29 amino acids of human growth hormone-releasing hormone (GHRH/GRF 1-29), originally developed by ConjuChem Biotechnologies. It carries four stabilizing amino acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) plus a lysine-linked maleimidopropionamide group constituting the Drug Affinity Complex (DAC). It is presented here as a research chemical for in vitro and preclinical investigational use only.

CJC-1295 with DAC — molecular structure (research illustration)

How CJC-1295 with DAC is studied

In research models, CJC-1295 acts as an agonist at the GHRH receptor (GRF receptor) on anterior pituitary somatotrophs. Its DAC moiety, a maleimide derivative, reacts covalently with a free thiol on circulating serum albumin, which substantially prolongs its plasma residence; published pharmacokinetic research has characterized an extended plasma half-life on the order of several days (estimated approximately 5.8 to 8.1 days; Teichman 2006). Receptor-binding studies and animal data describe activation of the GRF receptor and downstream cAMP/PKA signaling associated with growth hormone synthesis and release.

CJC-1295 with DAC — receptor & cell-signaling research illustration

Research areas

  • Studied as a long-acting GHRH/GRF receptor agonist in receptor-pharmacology research models (Jetté 2005, Endocrinology, rat pituitary)
  • Investigated in pharmacokinetic and pharmacodynamic research characterizing extended plasma half-life via albumin bioconjugation
  • Used as a research tool to study the somatotropic (GH/IGF-I) axis and pulsatile growth hormone secretion dynamics in preclinical and research settings
  • Examined in albumin-binding drug-delivery and peptide half-life-extension research (Drug Affinity Complex platform)
  • Referenced in comparative research on with-DAC versus no-DAC (Modified GRF 1-29) analog pharmacology

These describe laboratory/preclinical research only. No therapeutic, medical, or efficacy claims are made.

CJC-1295 with DAC research in a laboratory setting

CJC-1295 with DAC specifications

Class Synthetic long-acting growth hormone-releasing hormone (GHRH/GRF) analog with an albumin-binding Drug Affinity Complex (DAC)
Form Lyophilized powder (reconstitute with bacteriostatic water)
Purity standard ≥ 99% HPLC
Certificate of Analysis Available per batch on request
Use Research use only — not for human or veterinary use

Handling & quality

CJC-1295 with DAC is held to a ≥ 99% HPLC purity standard with a Certificate of Analysis available per batch. Reconstitute with bacteriostatic water and store refrigerated; handle strictly for research. See reconstitution & storage.

CJC-1295 with DAC vial — research-grade detail

Frequently asked questions

What is CJC-1295 with DAC?

CJC-1295 with DAC (also referred to in the literature as DAC:GRF) is a synthetic analog of the first 29 amino acids of human growth hormone-releasing hormone (GHRH/GRF 1-29), originally developed by ConjuChem Biotechnologies. It carries four stabilizing amino acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) plus a lysine-linked maleimidopropionamide group constituting the Drug Affinity Complex (DAC). It is presented here as a research chemical for in vitro and preclinical investigational use only.

Is CJC-1295 with DAC research use only?

Yes. CJC-1295 with DAC is supplied strictly for laboratory research — not for human or veterinary use, and not as a drug, food, or supplement.

Does Banger Labs provide a COA for CJC-1295 with DAC?

Yes — a Certificate of Analysis (HPLC purity + mass-spec identity) is available per batch on request. See the COA Library.

References

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (Teichman SL, et al.) — J Clin Endocrinol Metab. 2006 Mar;91(3):799-805 (PMID 16352683)
  2. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog (Jetté L, et al.) — Endocrinology. 2005 Jul;146(7):3052-8 (PMID 15817669)
  3. CJC-1295 — Wikipedia (overview, structure and developer)

Sources are provided for scientific reference and describe laboratory/preclinical research; they do not constitute medical advice or efficacy claims.

Shop CJC-1295 with DAC & related research peptides

Shop CJC-1295 with DAC →

By the Banger Labs Research Team. For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic. Educational information, not medical advice.